Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.

Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Markets and distributes specialty, artisanal and farmstead cheese products

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

AiCuris is a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria. AiCuris‘ mission is the development of innovative drugs against severe and life-threatening infectious diseases with high medical need. AiCuris aims to be THE successful innovator for antiviral and antibacterial therapy.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Zhu Hai Tai Nuo Mai Bo Zhi Yao Gu Fen You Xian Gong Si, established on 2015-12-17, Business scope includes general items:Medical Research and Experimental Development(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Natural science research and experimental development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Drug Wholesale;Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. It was established in 1994 and is headquartered in Lexington, Massachusetts.

Chiron Behring & Co., a subsidiary of Novartis AG, is a German company located in Marburg that supplies and developes new vaccine products for adults and children. The firm was acquired by Chiron Corp. from Hoechst AG on April 01, 1998 for $111.90 million.

VPM offers tailor-made consultancy and services based on in-depth experience in development of biopharmaceutical candidates. The company was established in 2002 following an initiative of the German Federal Ministry of Education and Research to promote the German market by funding vaccine development. Within the last decade, VPM has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs from academic research and brought them into clinical phase I and II trials.

Aicuris Anti-Infective Cures AG is a German company located in Wuppertal that engages in research and development in natural sciences, engineering, agricultural sciences and medicines. It was founded in 2006 by Helga R��bsamen-Schaeff. Holger Zimmermann is currently the CEO of the firm.

American Home Products LLC operates as a holding company which engages in the acquisition of niche manufacturers and distributors of functional and decorative architectural building and renovation products. These products are provided to the residential markets. The company was founded in 2014 and is headquartered in Van Nuys, CA.

4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.